US Pharma MarketingDaiichi Sankyo posts
Daiichi revealed on Friday it expects to post an “extraordinary” loss of 149.4 billion Japanese yen, or around $950 million. It is cutting its operating profit forecast by 106 billion Japanese yen ($677 million) for the fiscal year ending March 31. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy…
Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an "extraordinary loss" of 149.4 billion Japanese yen ($950 million) after overpromising demand for its ADCs to third-party manufacturers.
The Japanese company ...
Source: Endpoints News